267 related articles for article (PubMed ID: 38095831)
41. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
[TBL] [Abstract][Full Text] [Related]
42. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
[TBL] [Abstract][Full Text] [Related]
43.
Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
[TBL] [Abstract][Full Text] [Related]
44. Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.
Giacobbe DR; Bassetti M
Future Microbiol; 2022 Apr; 17():393-396. PubMed ID: 35234517
[No Abstract] [Full Text] [Related]
45. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
[TBL] [Abstract][Full Text] [Related]
46.
Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
[TBL] [Abstract][Full Text] [Related]
47. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
Delgado-Valverde M; Portillo-Calderón I; Alcalde-Rico M; Conejo MC; Hidalgo C; Del Toro Esperón C; Pascual Á
Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):445-457. PubMed ID: 38157139
[TBL] [Abstract][Full Text] [Related]
48. In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Bernabeu S; Dortet L
Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887194
[TBL] [Abstract][Full Text] [Related]
49.
Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
[TBL] [Abstract][Full Text] [Related]
50. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
[TBL] [Abstract][Full Text] [Related]
51. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
52. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
Sader HS; Mendes RE; Duncan L; Kimbrough JH; Carvalhaes CG; Castanheira M
Diagn Microbiol Infect Dis; 2023 Jun; 106(2):115945. PubMed ID: 37060707
[TBL] [Abstract][Full Text] [Related]
53. Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Poirel L; Ortiz de la Rosa JM; Sadek M; Nordmann P
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0003922. PubMed ID: 35315685
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602
[TBL] [Abstract][Full Text] [Related]
55. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
[TBL] [Abstract][Full Text] [Related]
56. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
Ruiz VH; Gill CM; Nicolau DP
J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443
[TBL] [Abstract][Full Text] [Related]
57. Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 May; 76(6):1511-1522. PubMed ID: 33760082
[TBL] [Abstract][Full Text] [Related]
58. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
Sader HS; Castanheira M; Huband M; Jones RN; Flamm RK
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242660
[TBL] [Abstract][Full Text] [Related]
59. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in
Hamrick JC; Docquier JD; Uehara T; Myers CL; Six DA; Chatwin CL; John KJ; Vernacchio SF; Cusick SM; Trout REL; Pozzi C; De Luca F; Benvenuti M; Mangani S; Liu B; Jackson RW; Moeck G; Xerri L; Burns CJ; Pevear DC; Daigle DM
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871094
[TBL] [Abstract][Full Text] [Related]
60. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
Sader HS; Mendes RE; Duncan LR; Carvalhaes CG; Castanheria M
J Antimicrob Chemother; 2022 Sep; 77(10):2642-2649. PubMed ID: 35897129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]